Research backs BNP (B-type natriuretic peptide) for predicting CHF (congestive heart failure):
This article was originally published in Clinica
Executive Summary
A US study has provided further evidence to support the use B-type natriuretic peptide (BNP) as a marker for congestive heart failure (CHF). Of 325 patients who presented at an emergency department with dyspnoea (shortness of breath), those with BNP concentrations four times that of the normal level had a 51% chance of either being admitted to the hospital with CHF or dying within six months. The study, by Alan Maisel of the University of California, San Diego and colleagues, appears in the Annals of Emergency Medicine (February 6).
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.